Anti-viral Drug Effective Against Coronavirus: Study Finds
Umer Jamshaid Published May 23, 2020 | 02:55 PM
Anti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night, three weeks after America's top infectious diseases expert said the study showed the medication has "clear-cut" benefits.
Washington, (UrduPoint / Pakistan Point News - 23rd May, 2020 ) :Anti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night, three weeks after America's top infectious diseases expert said the study showed the medication has "clear-cut" benefits.
Complete results from the research, which was carried out by US government agency the National Institute of Allergy and Infectious Diseases (NIAID), were published by leading medical periodical the New England Journal of Medicine.
The United States authorized the emergency use of remdesivir in hospitals on May 1, followed by Japan, while Europe is considering following suit.
The study found that remdesivir, injected intravenously daily for 10 days, accelerated the recovery of hospitalized COVID-19 patients compared to a placebo in clinical tests on just over a thousand patients across 10 countries.
On April 29, NIAID director Anthony Fauci, who has become the US government's trusted face on the coronavirus pandemic, said preliminary evidence indicated remdesivir had a "clear-cut, significant and positive effect in diminishing the time to recovery.
" The National Institutes of Health, of which the NIAID is a part, said Friday in a statement online that investigators found "remdesivir was most beneficial for hospitalized patients with severe disease who required supplemental oxygen." But the authors of the trial wrote that the drug did not prevent all deaths.
"Given high mortality despite the use of remdesivir, it is clear that treatment with an anti-viral drug alone is not likely to be sufficient," they said.
About 7.1 percent of patients given remdesivir in the trial group died within 14 days -- compared with 11.9 percent in the placebo group.
However, the result is just below the statistical reliability threshold, meaning it could be down to chance rather than the capability of the drug.
Related Topics
Recent Stories
Israel carries out attack inside Iran, report US media
Saudi Assistant Minister of Defence calls on army chief
Currency Rate In Pakistan - Dollar, Euro, Pound, Riyal Rates On 19 April 2024
Today Gold Rate in Pakistan 19 April 2024
Rock-solid Ruud racks up season-leading win in Barcelona
At UN, Iran says it will make Israel 'regret' reprisals
G7 hears calls for 'critical' Ukraine aid
EU seeks to leverage might to confront China, US challenge
5 Customs officials martyred as their vehicle ambushed by terrorists in D I Khan
Pak-New Zealand match called off due to rain
NHA restores traffic on roads affected by recent rains in Balochistan
China to fully support Pakistan's efforts against terrorism: Ambassador Jiang
More Stories From Health
-
DC calls for intensive anti-polio drive in ICT
20 hours ago -
World Hemophilia Day observed to underscore importance of providing comprehensive care
2 days ago -
Six in a family with heart on the 'right side'
2 days ago -
Diabetic disease increasing rapidly : Dr. Noor Elahi Memon
2 days ago -
World Hemophilia Day observed
2 days ago -
ATC dismisses bail petition of doctor involved in illegal kidneys transplant
10 days ago
-
Dr. Shehzad warns against deviation from WHO guidelines on anti-smoking
10 days ago -
Health activists express concerns over attempts to derail tobacco control
12 days ago -
UHS declares MBBS first prof, MS urology exam results
21 days ago -
Increased diagnostic testing for drug resistance
27 days ago -
IRD releases groundbreaking results of end TB programme
29 days ago -
Increased diagnostic testing for drug resistance TB will enhance patients’ treatment outcome
1 month ago